Thiamine and Ascorbic Acid in Sepsis and Septic Shock: A Review of Evidence for their Role in Practice.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Justin P Reinert, Kegan Becker, Martin J Ohlinger
{"title":"Thiamine and Ascorbic Acid in Sepsis and Septic Shock: A Review of Evidence for their Role in Practice.","authors":"Justin P Reinert, Kegan Becker, Martin J Ohlinger","doi":"10.1177/87551225251320873","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the evidence for the use of ascorbic acid, thiamine, or a combination of both agents without corticosteroids in the management of sepsis and septic shock.</p><p><strong>Data sources: </strong>A review of the literature was conducted through August 2023 on PubMed, MEDLINE, Web of Science, and CINAHL using the following terminology: \"ascorbic acid\" OR \"vitamin C\" OR \"thiamine\" OR \"vitamin B\" OR \"vitamin B 1\" AND \"sepsis\" OR \"septic shock\" NOT \"steroid\" OR \"hydrocortisone\" OR \"corticosteroid.\"</p><p><strong>Study selection and data extraction: </strong>Trials that described patient outcomes, medication efficacy, and medication safety data were considered for inclusion, while reports describing the use of either or both thiamine and ascorbic acid for a non-sepsis indication and reports that were not readily translatable to English were excluded. Studies that allowed corticosteroid use in both the intervention and control cohorts as part of a standard-of-care protocol were eligible for inclusion.</p><p><strong>Data synthesis: </strong>Heterogeneity of data exists, marked by divergent quantifications for successful pharmacotherapy interventions. Whereas some data support changes in patient outcome scores or critical illness indices, others have failed to demonstrate any meaningful benefit to ICU length of stay, ventilator status, or mortality.</p><p><strong>Conclusion: </strong>Exploring the individual and synergistic effects of ascorbic acid and thiamine on key pathways implicated in sepsis pathophysiology has not yielded unequivocal evidence supporting their use without concomitant corticosteroids.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251320873"},"PeriodicalIF":1.1000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866329/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225251320873","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate the evidence for the use of ascorbic acid, thiamine, or a combination of both agents without corticosteroids in the management of sepsis and septic shock.

Data sources: A review of the literature was conducted through August 2023 on PubMed, MEDLINE, Web of Science, and CINAHL using the following terminology: "ascorbic acid" OR "vitamin C" OR "thiamine" OR "vitamin B" OR "vitamin B 1" AND "sepsis" OR "septic shock" NOT "steroid" OR "hydrocortisone" OR "corticosteroid."

Study selection and data extraction: Trials that described patient outcomes, medication efficacy, and medication safety data were considered for inclusion, while reports describing the use of either or both thiamine and ascorbic acid for a non-sepsis indication and reports that were not readily translatable to English were excluded. Studies that allowed corticosteroid use in both the intervention and control cohorts as part of a standard-of-care protocol were eligible for inclusion.

Data synthesis: Heterogeneity of data exists, marked by divergent quantifications for successful pharmacotherapy interventions. Whereas some data support changes in patient outcome scores or critical illness indices, others have failed to demonstrate any meaningful benefit to ICU length of stay, ventilator status, or mortality.

Conclusion: Exploring the individual and synergistic effects of ascorbic acid and thiamine on key pathways implicated in sepsis pathophysiology has not yielded unequivocal evidence supporting their use without concomitant corticosteroids.

硫胺素和抗坏血酸在脓毒症和感染性休克中的作用:对其在实践中的作用证据的回顾。
目的:评价抗坏血酸、硫胺素或两种药物联合使用而不使用皮质类固醇治疗败血症和感染性休克的证据。数据来源:到2023年8月,在PubMed、MEDLINE、Web of Science和CINAHL上进行了文献回顾,使用以下术语:“抗坏血酸”或“维生素C”或“硫胺素”或“维生素B”或“维生素b1”和“败血症”或“感染性休克”,而不是“类固醇”或“氢化可的松”或“皮质类固醇”。“研究选择和数据提取:描述患者结局、药物疗效和药物安全性数据的试验被纳入考虑,而描述硫胺素和抗坏血酸用于非脓毒症指征的报告和不易翻译成英文的报告被排除。”允许在干预组和对照组中同时使用皮质类固醇作为标准治疗方案一部分的研究符合纳入条件。数据综合:数据存在异质性,以成功的药物治疗干预的不同量化为标志。虽然一些数据支持患者结局评分或危重疾病指数的变化,但其他数据未能证明对ICU住院时间、呼吸机状态或死亡率有任何有意义的益处。结论:探索抗坏血酸和硫胺素对脓毒症病理生理关键通路的个体和协同作用尚未得到明确的证据支持它们在不伴随皮质类固醇的情况下使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmacy Technology
Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-
CiteScore
1.50
自引率
0.00%
发文量
49
期刊介绍: For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信